Opens in a new tab

EOFLOW v Insulet (CFI, 15 February 2025)

Date15 February 2025
CourtCFI
DivisionMilan (IT) Central Division- Section
Type of actionGeneric application
Registry referenceApp_5366/2025 · ORD_7828/2025
PartiesInsulet Corporation

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By an order of 15 February 2025 (ORD_65815/2024, UPC_CFI_380/2024), Andrea Postiglione, judge rapporteur in the Milan Central Division, dismissed without examining the substance EOFLOW Co., Ltd.’s application for its costs in the provisional measures proceedings brought by Insulet Corporation on EP 4 201 327, which had been dismissed. The order settles a question of timing: the costs of provisional measures proceedings followed by an action on the merits or by an appeal are decided with the merits.

Question

May a party that has defeated an application for provisional measures recover its costs immediately, while merits proceedings and an appeal are pending?

Decision

The judge noted that Rule 150 provides for cost proceedings after the decision on the merits, and that Art. 69 UPCA lays down a general rule not confined to merits decisions (paragraphs 10 to 12). Following the same division’s order of 23 December 2024, he accepted that some sub-proceedings may ground a costs claim, but only where they fully satisfy the applicant and end at the interim stage (paragraphs 15 to 18). That is not so where a merits action follows, here Insulet’s infringement counterclaim, or where the order is appealed (paragraphs 19 to 21). The summary nature of interim review, the risk of double assessment and of non-final payments, and the principles of proportionality and flexibility justify deciding costs together with the merits (paragraphs 22 to 28). Leave to appeal was granted.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Art. 69
Rules of Procedure
Rules 150, 151, 157, 206, 213, 221 and 295
Case law cited
Milan Central Division order of 23 December 2024 (ORD_59988/2024), Court of Appeal, App. 283/2025 (date not stated)

Related decisions

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.

Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.

Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Generic application
Outcome (Dhenne Avocats summary)
Le juge rapporteur rejette sans examen au fond la demande de frais d'EOFLOW, les frais de la procédure de mesures provisoires devant être appréciés à l'issue de la procédure au fond et de l'appel pendant.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 4 201 327
Fluid delivery device with transcutaneous access tool, insertion mechanism and blood glucose monitoring for use therewith
recorded proprietor: Insulet Corp
Mentioned in the analysis (role not qualified)
Also mentioned in 25 other decision(s): EOFLOW v Insulet (CFI, 22 July 2025) · EOFLOW v Insulet (CoA, 18 March 2026) · EOFlow v Insulet (CoA, 26 February 2026) · EOFlow v Insulet (CoA, 4 February 2026) · EOFlow v Insulet (CoA, 29 January 2026) · Herbert Smith Freehills Kramer (applicant) in Insulet v EOFLow (CoA, 2 · Insulet v EOFLOW (CFI, 15 October 2025) · EOFLOW v Insulet (CFI, ORD_26828/2025, 5 June 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.